Literature DB >> 31606272

AUTACs: Cargo-Specific Degraders Using Selective Autophagy.

Daiki Takahashi1, Jun Moriyama1, Tomoe Nakamura1, Erika Miki1, Eriko Takahashi1, Ayami Sato1, Takaaki Akaike2, Kaori Itto-Nakama1, Hirokazu Arimoto3.   

Abstract

Protein silencing represents an essential tool in biomedical research. Targeted protein degradation (TPD) strategies exemplified by PROTACs are rapidly emerging as modalities in drug discovery. However, the scope of current TPD techniques is limited because many intracellular materials are not substrates of proteasomal clearance. Here, we described a novel targeted-clearance strategy (autophagy-targeting chimera [AUTAC]) that contains a degradation tag (guanine derivatives) and a warhead to provide target specificity. As expected from the substrate scope of autophagy, AUTAC degraded fragmented mitochondria as well as proteins. Mitochondria-targeted AUTAC accelerated both the removal of dysfunctional fragmented mitochondria and the biogenesis of functionally normal mitochondria in patient-derived fibroblast cells. Cytoprotective effects against acute mitochondrial injuries were also seen. Canonical autophagy is viewed as a nonselective bulk decomposition system, and none of the available autophagy-inducing agents exhibit useful cargo selectivity. With its target specificity, AUTAC provides a new modality for research on autophagy-based drugs.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AUTAC; Down syndrome; K63-linked polyubiquitin; PROTACs; S-guanylation; autophagy; cargo-specific degrader; drug discovery; mitophagy; targeted protein degradation

Mesh:

Substances:

Year:  2019        PMID: 31606272     DOI: 10.1016/j.molcel.2019.09.009

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  70 in total

Review 1.  Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective.

Authors:  Xinrui Yang; He Yin; Richard D Kim; Jason B Fleming; Hao Xie
Journal:  Target Oncol       Date:  2020-12-28       Impact factor: 4.493

Review 2.  PROTACs: great opportunities for academia and industry.

Authors:  Xiuyun Sun; Hongying Gao; Yiqing Yang; Ming He; Yue Wu; Yugang Song; Yan Tong; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2019-12-24

Review 3.  The PROTACtable genome.

Authors:  Melanie Schneider; Chris J Radoux; Andrew Hercules; David Ochoa; Ian Dunham; Lykourgos-Panagiotis Zalmas; Gerhard Hessler; Sven Ruf; Veerabahu Shanmugasundaram; Michael M Hann; Pam J Thomas; Markus A Queisser; Andrew B Benowitz; Kris Brown; Andrew R Leach
Journal:  Nat Rev Drug Discov       Date:  2021-07-20       Impact factor: 84.694

Review 4.  Protein phase separation: A novel therapy for cancer?

Authors:  Wei Wang; Yingqian Chen; Aixiao Xu; Minyi Cai; Ji Cao; Hong Zhu; Bo Yang; Xuejing Shao; Meidan Ying; Qiaojun He
Journal:  Br J Pharmacol       Date:  2020-09-28       Impact factor: 8.739

Review 5.  Multispecific drugs herald a new era of biopharmaceutical innovation.

Authors:  Raymond J Deshaies
Journal:  Nature       Date:  2020-04-15       Impact factor: 49.962

Review 6.  Emerging New Concepts of Degrader Technologies.

Authors:  Yu Ding; Yiyan Fei; Boxun Lu
Journal:  Trends Pharmacol Sci       Date:  2020-04-23       Impact factor: 14.819

7.  Targeting selective autophagy by AUTAC degraders.

Authors:  Daiki Takahashi; Hirokazu Arimoto
Journal:  Autophagy       Date:  2020-01-20       Impact factor: 16.016

Review 8.  Mitophagy in Human Diseases.

Authors:  Laura Doblado; Claudia Lueck; Claudia Rey; Alejandro K Samhan-Arias; Ignacio Prieto; Alessandra Stacchiotti; Maria Monsalve
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923

9.  Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development.

Authors:  Pan Tang; Jifa Zhang; Jie Liu; Cheng-Ming Chiang; Liang Ouyang
Journal:  J Med Chem       Date:  2021-02-22       Impact factor: 7.446

Review 10.  Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases.

Authors:  Jinsha Liu; Joey Paolo Ting; Shams Al-Azzam; Yun Ding; Sepideh Afshar
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.